Regulatory claims made by US businesses engaged in direct-to-consumer marketing of purported stem cell treatments and exosome therapies
Aim: This study investigated whether US businesses engaged in direct-to-consumer online marketing of purported stem cell therapies and stem cell-derived exosome products made claims concerning the regulatory status of these interventions. Methods: We used data mining and content analysis of company websites to examine regulatory-related representations made by US businesses marketing stem cell treatments and exosome therapies. Results: More than two thirds of such businesses did not make explicit representations about the regulatory status of their marketed products. Businesses that made claims about the regulatory status of the stem cell and exosome products they sold used range of representations concerning the legal standing of these interventions. Conclusion: The absence of information addressing the regulatory status of stem cell interventions and exosome products and the use of what appeared to be inaccurate information concerning the regulatory status of numerous products likely complicates efforts by customers to make informed health-related decisions.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Regenerative medicine - 18(2023), 11 vom: 22. Nov., Seite 857-868 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Turner, Leigh [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Direct-to-consumer online advertising |
|---|
| Anmerkungen: |
Date Completed 27.11.2023 Date Revised 04.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2217/rme-2023-0117 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363596356 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363596356 | ||
| 003 | DE-627 | ||
| 005 | 20231226093702.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/rme-2023-0117 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1211.xml |
| 035 | |a (DE-627)NLM363596356 | ||
| 035 | |a (NLM)37867326 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Turner, Leigh |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Regulatory claims made by US businesses engaged in direct-to-consumer marketing of purported stem cell treatments and exosome therapies |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.11.2023 | ||
| 500 | |a Date Revised 04.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Aim: This study investigated whether US businesses engaged in direct-to-consumer online marketing of purported stem cell therapies and stem cell-derived exosome products made claims concerning the regulatory status of these interventions. Methods: We used data mining and content analysis of company websites to examine regulatory-related representations made by US businesses marketing stem cell treatments and exosome therapies. Results: More than two thirds of such businesses did not make explicit representations about the regulatory status of their marketed products. Businesses that made claims about the regulatory status of the stem cell and exosome products they sold used range of representations concerning the legal standing of these interventions. Conclusion: The absence of information addressing the regulatory status of stem cell interventions and exosome products and the use of what appeared to be inaccurate information concerning the regulatory status of numerous products likely complicates efforts by customers to make informed health-related decisions | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a US FDA | |
| 650 | 4 | |a US Food and Drug Administration | |
| 650 | 4 | |a US federal regulations | |
| 650 | 4 | |a direct-to-consumer online advertising | |
| 650 | 4 | |a regulatory claims | |
| 650 | 4 | |a state legislation | |
| 650 | 4 | |a stem cell interventions | |
| 700 | 1 | |a Martinez, Juan Ramon |e verfasserin |4 aut | |
| 700 | 1 | |a Najjar, Shemms |e verfasserin |4 aut | |
| 700 | 1 | |a Arachchilage, Thevin Rajapaksha |e verfasserin |4 aut | |
| 700 | 1 | |a Sahrai, Victoria |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Jia Chieng |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Regenerative medicine |d 2006 |g 18(2023), 11 vom: 22. Nov., Seite 857-868 |w (DE-627)NLM169957144 |x 1746-076X |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2023 |g number:11 |g day:22 |g month:11 |g pages:857-868 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/rme-2023-0117 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2023 |e 11 |b 22 |c 11 |h 857-868 | ||